MX2022002360A - Anticuerpos de anti-il31 para uso veterinario. - Google Patents

Anticuerpos de anti-il31 para uso veterinario.

Info

Publication number
MX2022002360A
MX2022002360A MX2022002360A MX2022002360A MX2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A
Authority
MX
Mexico
Prior art keywords
antibodies
feline
canine
veterinary use
enhanced binding
Prior art date
Application number
MX2022002360A
Other languages
English (en)
Inventor
Shyr Jiann Li
Lam Nguyen
Hangjun Zhan
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of MX2022002360A publication Critical patent/MX2022002360A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan diversas modalidades relacionadas con anticuerpos anti-IL31 que tienen la unión mejorada a IL31 canina e IL31 felina; tales anticuerpos pueden usarse en métodos para tratar afecciones inducidas por IL31 en animales de compañía, tales como caninos caninas y felinas.
MX2022002360A 2019-08-29 2020-08-28 Anticuerpos de anti-il31 para uso veterinario. MX2022002360A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893799P 2019-08-29 2019-08-29
US201962894526P 2019-08-30 2019-08-30
PCT/US2020/048618 WO2021041972A1 (en) 2019-08-29 2020-08-28 Anti-il31 antibodies for veterinary use

Publications (1)

Publication Number Publication Date
MX2022002360A true MX2022002360A (es) 2022-04-06

Family

ID=74686094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002360A MX2022002360A (es) 2019-08-29 2020-08-28 Anticuerpos de anti-il31 para uso veterinario.

Country Status (10)

Country Link
US (1) US20220324960A1 (es)
EP (1) EP4021499A1 (es)
JP (1) JP2022545259A (es)
KR (1) KR20220071191A (es)
CN (1) CN114555121A (es)
AU (1) AU2020336210A1 (es)
BR (1) BR112022002771A2 (es)
CA (1) CA3147809A1 (es)
MX (1) MX2022002360A (es)
WO (1) WO2021041972A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN114989299B (zh) * 2022-06-21 2023-05-26 北京索莱宝科技有限公司 一种单克隆抗体的组合物及其应用、检测人白细胞介素1β的试剂、试剂盒和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695124B2 (en) * 1993-05-28 1998-08-06 Scripps Research Institute, The Methods and compositions for inhibiting CD14 mediated cell activation
SI2594586T1 (sl) * 2006-09-01 2014-11-28 Zymogenetics, Inc. IL-31 monoklonska protitelesa in metode uporabe
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
CA2980992C (en) * 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
MA44776A (fr) * 2016-04-15 2019-03-06 Immunext Inc Anticorps anti-vista humain et leur utilisation
WO2018156180A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JP7250032B2 (ja) * 2017-12-11 2023-03-31 ユービーアイ アイピー ホールディングス アトピー性皮膚炎の治療及び／または予防のためのｉｌ－３１のペプチド免疫原ならびにその製剤

Also Published As

Publication number Publication date
CN114555121A (zh) 2022-05-27
BR112022002771A2 (pt) 2022-08-09
US20220324960A1 (en) 2022-10-13
KR20220071191A (ko) 2022-05-31
AU2020336210A1 (en) 2022-03-03
JP2022545259A (ja) 2022-10-26
WO2021041972A1 (en) 2021-03-04
CA3147809A1 (en) 2021-03-04
EP4021499A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
MX2021002971A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
MX2014000803A (es) Anticuerpo monoclonal de interleucina-31.
MX2022002360A (es) Anticuerpos de anti-il31 para uso veterinario.
AU2018254542A1 (en) IL4/IL13 receptor molecule for veterinary use
MXPA06010715A (es) Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
MX2014011051A (es) Anticuerpos con cadena ligera modificada con histidina por ingenieria genetica y animales no humanos geneticamente modificados para generarlos.
PH12014501927A1 (en) Antibodies to matrix metalloproteinase 9
MX342413B (es) Anticuerpos para metaloproteinasa-9 de matriz.
MX357308B (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina.
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201890907A1 (ru) МУТИРОВАННЫЕ Fc АНТИТЕЛА С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
MX2014010449A (es) Anticuerpos a metaloproteinasa de matriz 9.
BR112012022342A2 (pt) anticorpos monoclonais dirigidos a cd52
AR096671A1 (es) Método para preparar una composición de aditivos para alimento para animales
JP2013520999A5 (es)
EA201991203A1 (ru) Способы лечения ожирения антителами к angptl8
EA201891499A1 (ru) Химерное собачье анти-cd20 антитело
MX2022011335A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
MX2022013149A (es) Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario.
JP2013520990A5 (es)
MX2022013147A (es) Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario.
MX370755B (es) Mejoradores de la palatabilidad para alimentos diseñados para perros y gatos con insuficiencia renal.